ArticleCommunications biology2026
The MYB-related transcription factor MYPOP acts as a selective regulator of cancer cell growth.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
The MYB-related transcription factor and partner of profilin (MYPOP or p42POP) is a ubiquitously expressed yet understudied protein recently identified as a restriction factor of oncogenic human papillomaviruses (HPV) and proposed tumor suppressor. Here we show that in HPV-transformed cervical cancer cells, MYPOP induces alterations in cell morphology, silences viral and cellular oncogenes including E6 and MYC, and stimulates the release of the cancer-killing cytokine interleukin-24. Transcriptomic and live-cell analyses reveal a rapid G1/S-phase arrest followed by loss of viable cervical cancer cells and induction of apoptosis. Moreover, MYPOP expression is broadly diminished across multiple human cancers, and its re-expression by both DNA- and mRNA-gene transfer markedly suppresses tumor cell proliferation while sparing normal epidermal keratinocytes. Similarly, murine Mypop inhibits mouse cancer cell growth. Collectively, our findings identify MYPOP as a selective suppressor of tumor cell proliferation across species in vitro and point to its potential relevance for future therapeutic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.